For most of the twentieth century, immunologists assumed inflammation ended the way a fire dies — by burning through its fuel. That assumption collapsed in the early 2000s when Charles Serhan’s lab at Harvard identified a family of lipid mediators that don’t just dampen inflammation but actively orchestrate its termination. These molecules — resolvins, protectins, and maresins — are biosynthesized from EPA and DHA on demand at sites of injury, and they reveal that resolution is a distinct biochemical program with its own enzymes, receptors, and signaling logic.
What Are Specialized Pro-Resolving Mediators?
Specialized pro-resolving mediators (SPMs) are endogenous lipid mediators enzymatically derived from omega-3 polyunsaturated fatty acids — primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) — as well as the omega-6 arachidonic acid in the case of lipoxins. The major SPM families include resolvins (E-series from EPA, D-series from DHA), protectins (from DHA), maresins (from DHA, produced by macrophages), and lipoxins (from arachidonic acid). They were discovered and structurally characterized through self-resolving exudate studies by Charles N. Serhan and colleagues, establishing that resolution is an active, agonist-driven process rather than passive decay of pro-inflammatory signaling.[1]
Unlike anti-inflammatory drugs that block inflammatory pathways (NSAIDs inhibiting COX, corticosteroids suppressing transcription), SPMs work by agonizing resolution receptors — GPR32, ChemR23 (CMKLR1), ALX/FPR2, and others — that exist specifically to switch off neutrophil recruitment, drive macrophage efferocytosis, and restore tissue homeostasis.[2]
How SPMs Work
Biosynthesis at the Site of Injury: SPMs are generated in a tightly regulated sequence. During acute inflammation, a “lipid mediator class switch” occurs in which prostaglandin E2 and D2 transcriptionally upregulate 15-lipoxygenase (15-LOX) in neutrophils, shifting the substrate pool from arachidonic acid toward EPA and DHA. Sequential lipoxygenation by 15-LOX, 5-LOX, and in some cases 12-LOX yields the trihydroxy and dihydroxy SPM structures. This class switch is the molecular event that flips inflammation from initiation to resolution.[1]
Receptor-Mediated Signaling: Each SPM family signals through specific G-protein-coupled receptors. Resolvin E1 binds ChemR23 (and partially antagonizes BLT1, the LTB4 receptor on neutrophils). Resolvin D1 signals through ALX/FPR2 and GPR32. Maresin 1 binds LGR6. Engagement of these receptors halts further neutrophil infiltration, stops the production of pro-inflammatory cytokines, and licenses macrophages to clear apoptotic neutrophils.[2]
Macrophage Reprogramming: A defining action of SPMs is the transition of macrophages from an M1 (pro-inflammatory) to an M2-like (pro-resolving, tissue-repair) phenotype. SPMs increase macrophage efferocytosis — the engulfment of apoptotic neutrophils — by several-fold, which is essential because uncleared apoptotic cells undergo secondary necrosis and perpetuate inflammation. Maresin 1, produced by macrophages themselves, is particularly potent in this regard and also promotes tissue regeneration in planaria and mammalian models.[3]
Termination Without Immunosuppression: A critical distinction from glucocorticoids is that SPMs do not impair host defense. They enhance bacterial clearance, lower antibiotic doses required for clearance in sepsis models, and shorten the inflammatory phase without prolonging vulnerability to infection. Resolution is achieved by accelerating the program, not by silencing immunity.[4]
Clinical and Translational Evidence
Cardiovascular Disease: Atherosclerotic lesions show a disrupted ratio of pro-inflammatory leukotrienes to pro-resolving lipoxins and resolvins. Work from Ira Tabas and colleagues demonstrated that vulnerable human plaques have markedly lower SPM/leukotriene ratios than stable plaques, and that administering resolvin D1 to mice with advanced atherosclerosis stabilizes lesions, reduces necrotic core size, and enhances efferocytosis of plaque macrophages — without lowering LDL.[5]
Chronic Inflammatory Disease: SPM deficits have been documented in rheumatoid arthritis, inflammatory bowel disease, periodontitis, and chronic obstructive pulmonary disease. In animal models of colitis, arthritis, and periodontal bone loss, exogenous resolvins and lipoxins resolve disease at nanogram-to-microgram doses with no detectable immunosuppression. Resolvin E1 in particular has shown protective effects in periodontal disease models, restoring bone and reversing tissue damage.[2]
Pain and Neuroinflammation: Resolvins exert potent analgesic effects in inflammatory and neuropathic pain models at doses orders of magnitude lower than NSAIDs. The mechanism involves TRPV1 and TRPA1 modulation on sensory neurons in addition to peripheral immune effects, suggesting SPMs operate at the interface of immunity and nociception.[3]
Sepsis and Infection: In murine peritonitis and pneumonia models, SPM administration improves survival, accelerates bacterial clearance, and reduces organ damage. This counterintuitive finding — that a pro-resolving agonist enhances rather than impairs antimicrobial defense — has reframed the conceptual approach to sepsis from suppression of cytokine storm toward acceleration of resolution.[4]
Human Data on Omega-3 Supplementation and SPMs
Although purified SPMs are not yet available as therapeutics, oral EPA/DHA supplementation reliably increases circulating SPM concentrations in humans. Studies measuring 18-HEPE, 17-HDHA, and 14-HDHA (SPM pathway markers) by LC-MS/MS show dose-dependent elevations after fish oil intake, and clinical responses to omega-3 therapy in cardiovascular and inflammatory conditions correlate with the magnitude of SPM pathway induction rather than with raw EPA/DHA levels alone. This provides a mechanistic framework for understanding why omega-3 trials show heterogeneous results: the relevant outcome is SPM biosynthesis capacity, which depends on substrate availability and on lipoxygenase enzyme function.[1]
Safety Profile
SPMs are endogenous molecules that act at nanomolar to picomolar concentrations through specific receptors, and unlike NSAIDs or corticosteroids they do not appear to impair host defense, gastric mucosal integrity, or HPA axis function in preclinical models. The omega-3 precursors EPA and DHA are well-tolerated in doses up to several grams per day in humans, with the main considerations being mild gastrointestinal upset and a theoretical antiplatelet effect at higher doses. Synthetic SPM analogs are in development to overcome the rapid metabolic inactivation of native SPMs (often by further oxidation at the 17- or 18-position), but as of this writing no purified SPM has received regulatory approval as a drug.
SPMs vs Conventional Anti-Inflammatory Approaches
Versus NSAIDs: NSAIDs block COX enzymes and thereby suppress prostaglandin synthesis — including the prostaglandins that trigger the lipid mediator class switch toward resolution. Paradoxically, this means that chronic NSAID use can impair the resolution program itself. SPMs work downstream and in parallel, terminating inflammation without preventing its initial protective phase.[1]
Versus Corticosteroids: Glucocorticoids broadly suppress immune transcription, including resolution programs, and impair efferocytosis at higher doses. SPMs specifically enhance efferocytosis and macrophage reprogramming without systemic immunosuppression.[3]
Versus Biologics: Anti-TNF and anti-IL-6 therapies neutralize specific cytokines but do not address the underlying failure of resolution that characterizes chronic inflammatory disease. The SPM framework suggests that many chronic inflammatory conditions are better understood as resolution-deficient rather than inflammation-excessive states — a conceptual shift with implications for combination therapy.[2]
Clinical Implications
The SPM framework reframes several therapeutic questions. In cardiovascular disease, the question is not only whether omega-3s lower triglycerides but whether they restore resolution capacity in arterial macrophages. In autoimmune disease, persistent inflammation may reflect a biosynthetic block in the SPM pathway — sometimes correctable with EPA/DHA, sometimes requiring direct agonism. And in the aging immune system, declining SPM production and receptor expression may contribute to inflammaging, the chronic low-grade inflammation associated with most age-related diseases. As stable SPM analogs advance through development, the prospect of pharmacologically driving resolution — rather than blocking inflammation — represents one of the more conceptually distinct directions in immunopharmacology of the past two decades.
References
- Serhan CN. “Pro-resolving lipid mediators are leads for resolution physiology.” Nature. 2014;510(7503):92-101.
- Serhan CN, Levy BD. “Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators.” Journal of Clinical Investigation. 2018;128(7):2657-2669.
- Serhan CN, Chiang N, Dalli J. “The resolution code of acute inflammation: novel pro-resolving lipid mediators in resolution.” Seminars in Immunology. 2015;27(3):200-215.
- Chiang N, Serhan CN. “Specialized pro-resolving mediator network: an update on production and actions.” Essays in Biochemistry. 2020;64(3):443-462.
- Fredman G, Hellmann J, Proto JD, et al. “An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques.” Nature Communications. 2016;7:12859.
